p53: puzzle and paradigm.
Open accessThe DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Abstract
As the tale of p53 unfolds, it becomes ever more intriguing.Although our understanding of the critical and complex roles played by p53 is progressing rapidly, new findings continue to pose new paradoxes.Here we present some of these recent advances in p53 research and discuss how they either shed light on or add to the complexities of p53.Therefore, we only briefly summarize some of the key developments leading to our current state of knowledge.For further information, the reader is referred to several excellent reviews that have focused on p53 research (see Donehower and Bradley 1993;
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 3×
“The ability to generate mice lacking p53 implied that p53 is dispensable for growth, differentiation, and embryonic development (Donehower et al. 1992).”
BackgroundVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 4,296
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,961
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Cited by
Items 201–300 of 302
The E2F transcription factors: key regulators of cell proliferation
Müller, H., & Helin, K. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(99)00030-x · Cited by 260
Galbiati, F., Volonte', D., Liu, J., Capozza, F., Frank, P. G., Zhu, L., Pestell, R. G., & Lisanti, M. P. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.8.2229 · Cited by 259
Xu, D., Wang, Q., Gruber, A., Björkholm, M., Chen, Z., Zaid, A., Selivanova, G., Peterson, C., Wiman, K. G., & Pisa, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203890 · Cited by 257
“…may result from its direct interaction with transcription factors or protein components of the transcription machinery such as the TATA binding protein (TBP), TATA associated factors (TAFs), CCAAT-binding factor (CBF) and Sp1 (Bargonetti et al., 1997; Ko and Prives, 1996; Perrem et al., 1995).”
BackgroundInfluentialRB Regulates the Stability and the Apoptotic Function of p53 via MDM2
Hsieh, J.-K., Chan, F. S. G., O’Connor, D. J., Mittnacht, S., Zhong, S., & Lu, X. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80309-3 · Cited by 255
Majumder, M., Ghosh, A. K., Steele, R., Ray, R., & Ray, R. B. (2001) · Journal of Virology · doi:10.1128/jvi.75.3.1401-1407.2001 · Cited by 255
Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer
Li, Y., Hively, W. P., & Varmus, H. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203273 · Cited by 255
Apoptosis in Alzheimer's disease—an update
Shimohama, S. (2000) · Apoptosis · doi:10.1023/a:1009625323388 · Cited by 253
Transcriptional Activation of the Human Glutathione Peroxidase Promoter by p53
Tan, M., Li, S., Swaroop, M., Guan, K., Oberley, L. W., & Sun, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.12061 · Cited by 253
p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage
Chao, C. (2000) · The EMBO Journal · doi:10.1093/emboj/19.18.4967 · Cited by 252
Midgley, C. A., Desterro, J. M., Saville, M. K., Howard, S., Sparks, A., Hay, R. T., & Lane, D. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203593 · Cited by 252
Partial rescue of Brca15–6 early embryonic lethality by p53 or p21 null mutation
Hakem, R., de la Pompa, J. L., Elia, A., Potter, J., & Mak, T. W. (1997) · Nature Genetics · doi:10.1038/ng0797-298 · Cited by 252
Tan, M., Wang, Y., Guan, K., & Sun, Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.109 · Cited by 252
Itahana, K., Mao, H., Jin, A., Itahana, Y., Clegg, H. V., Lindström, M. S., Bhat, K. P., Godfrey, V. L., Evan, G. I., & Zhang, Y. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.09.007 · Cited by 245
HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis
Lan, K.-H., Sheu, M.-L., Hwang, S.-J., Yen, S.-H., Chen, S.-Y., Wu, J.-C., Wang, Y.-J., Kato, N., Omata, M., Chang, F.-Y., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205589 · Cited by 245
“Inhibition of its ability to regulate transcription by mutations or by association with viral oncoproteins correlates with oncogenesis (Ko and Prives, 1996; Levine, 1993).”
BackgroundFeng, L., Lin, T., Uranishi, H., Gu, W., & Xu, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5389-5395.2005 · Cited by 236
“In response to genotoxic and cellular stresses, the stability and activity of p53 are greatly induced, leading to cell cycle arrest, DNA repair, and/or apoptosis, depending on the cell types (1, 2, 21, 32, 39, 40).”
BackgroundAutoinhibitory Domains: Modular Effectors of Cellular Regulation
Pufall, M. A., & Graves, B. J. (2002) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.18.031502.133614 · Cited by 236
Ambs, S., Hussain, S. P., & Harris, C. C. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.6.9194524 · Cited by 233
The N-terminal Domain of p53 is Natively Unfolded
Dawson, R., Müller, L., Dehner, A., Klein, C., Kessler, H., & Buchner, J. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.08.008 · Cited by 229
Wang, X., Kua, H.-Y., Hu, Y., Guo, K., Zeng, Q., Wu, Q., Ng, H.-H., Karsenty, G., de Crombrugghe, B., Yeh, J., et al. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200507106 · Cited by 225
Negative regulation of bcl-2 expression by p53 in hematopoietic cells
Wu, Y.-L., Mehew, J. W., Heckman, C. A., Arcinas, M., & Boxer, L. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204067 · Cited by 221
“…that individual hot spot mutants di er in their properties, and they do not necessarily behave in a similar fashion and that some mutants, particularly 273 and 143, can, in some circumstances, adopt wild-type properties regarding DNA-binding and transcriptional function (Ko and Prives, 1996).”
BackgroundRegional analysis of p53 mutations in rheumatoid arthritis synovium
Yamanishi, Y., Boyle, D. L., Rosengren, S., Green, D. R., Zvaifler, N. J., & Firestein, G. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152333199 · Cited by 214
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Liu, G., & Chen, X. (2002) · Oncogene · doi:10.1038/sj.onc.1205862 · Cited by 207
“These domains are critical for p53 activity (Ko and Prives, 1996).”
Backgroundvon der Thüsen, J. H., van Vlijmen, B. J. M., Hoeben, R. C., Kockx, M. M., Havekes, L. M., van Berkel, T. J. C., & Biessen, E. A. L. (2002) · Circulation · doi:10.1161/01.cir.0000015502.97828.93 · Cited by 203
Cuddihy, A. R., Hoi-Tao Wong, A., Wai Ning Tam, N., Li, S., & Koromilas, A. E. (1999) · Oncogene · doi:10.1038/sj.onc.1202620 · Cited by 203
“Normally present at low levels in a cell, the onset of DNA damage or cellular stress causes the accumulation of p53 protein (Ko and Prives, 1996; Levine, 1997). p53 then utilizes its capacity as a transcription factor to induce the expression of a number of genes that ultimately induce a state of…”
InfluentialReactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 202
A transactivation-deficient mouse model provides insights into Trp53 regulation and function
Jimenez, G. S., Nister, M., Stommel, J. M., Beeche, M., Barcarse, E. A., Zhang, X.-Q., O'Gorman, S., & Wahl, G. M. (2000) · Nature Genetics · doi:10.1038/79152 · Cited by 196
“gif" NDATA ITEM> ]> Introduction The Trp53 tumour-suppressor protein induces cell-cycle arrest or apoptosis in response to diverse stresse”
Kobet, E., Zeng, X., Zhu, Y., Keller, D., & Lu, H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.23.12547 · Cited by 194
Overholtzer, M., Rao, P. H., Favis, R., Lu, X.-Y., Elowitz, M. B., Barany, F., Ladanyi, M., Gorlick, R., & Levine, A. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934852100 · Cited by 193
Aust, A. E., & Eveleigh, J. F. (1999) · Proceedings of the Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.1999.d01-141.x · Cited by 191
Young, K. H., Leroy, K., Møller, M. B., Colleoni, G. W. B., Sánchez-Beato, M., Kerbauy, F. R., Haioun, C., Eickhoff, J. C., Young, A. H., Gaulard, P., et al. (2008) · Blood · doi:10.1182/blood-2008-01-129783 · Cited by 191
“III/IV 137 (54) 107 (57) 30 (48) B symptoms”
p53 is a general repressor of RNA polymerase III transcription
Cairns, C. A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3112 · Cited by 190
“The p53 protein displays a variety of biochemical activities, including the ability to regulate transcription (Cox and Lane, 1995; Haffner and Oren, 1995; Ko and Prives, 1996; Levine, 1997).”
InfluentialA planarian p53 homolog regulates proliferation and self-renewal in adult stem cell lineages
Pearson, B. J., & Alvarado, A. S. (2010) · Development · doi:10.1242/dev.044297 · Cited by 188
Regulation of p53 stability and activity in response to genotoxic stress
Colman, M. S., Afshari, C. A., & Barrett, J. C. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00035-1 · Cited by 183
The AML1/ETO fusion protein activates transcription of BCL-2
Klampfer, L., Zhang, J., Zelenetz, A. O., Uchida, H., & Nimer, S. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14059 · Cited by 182
Mirzayans, R., Andrais, B., & Murray, D. (2018) · Cancers · doi:10.3390/cancers10040118 · Cited by 181
Radiation-Induced Senescence-like Growth Arrest Requires TP53 Function but not Telomere Shortening
Suzuki, K., Mori, I., Nakayama, Y., Miyakoda, M., Kodama, S., & Watanabe, M. (2001) · Radiation Research · doi:10.1667/0033-7587(2001)155[0248:rislga]2.0.co;2 · Cited by 179
hMutSα- and hMutLα-dependent phosphorylation of p53 in response to DNA methylator damage
Duckett, D. R., Bronstein, S. M., Taya, Y., & Modrich, P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12384 · Cited by 178
Pathology of hereditary breast cancer
van der Groep, P., van der Wall, E., & van Diest, P. J. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0010-3 · Cited by 177
The role of p53 in neuronal cell death
Morrison, R. S., & Kinoshita, Y. (2000) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400741 · Cited by 174
“± 7 The p53 protein is upregulated in response to a diverse array of cellular stresses, including DNA damage, hypoxia, oxidative stress, ribonucleotide depletion and oncogene activation.(8,9) p53 protein levels are largely regulated in response to injury by changes in protein degradation.”
Backgroundp53 Is Phosphorylated by CDK7-Cyclin H in a p36MAT1-Dependent Manner
Ko, L. J., Shieh, S.-Y., Chen, X., Jayaraman, L., Tamai, K., Taya, Y., Prives, C., & Pan, Z.-Q. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.12.7220 · Cited by 173
“The tumor suppressor protein p53 is a transcriptional activator that mediates cellular responses to genotoxic stress (20, 30, 35).”
BackgroundSelf-citationp53RDL1 regulates p53-dependent apoptosis
Tanikawa, C., Matsuda, K., Fukuda, S., Nakamura, Y., & Arakawa, H. (2003) · Nature Cell Biology · doi:10.1038/ncb943 · Cited by 173
Neuroprotective Effects of Huperzine A
Wang, R., & Tang, X. C. (2005) · Neurosignals · doi:10.1159/000085387 · Cited by 173
Bykov, V. J. N. (2002) · Carcinogenesis · doi:10.1093/carcin/23.12.2011 · Cited by 172
Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor
Fernandez-Fernandez, M. R., Veprintsev, D. B., & Fersht, A. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501459102 · Cited by 171
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo
Xirodimas, D., Saville, M. K., Edling, C., Lane, D. P., & Laín, S. (2001) · Oncogene · doi:10.1038/sj.onc.1204656 · Cited by 169
“This results in the induction of p53 transcriptional activity and consequent expression of genes whose products cause cell cycle arrest or induction of apoptosis (Oren, 1999; Levine, 1997; Ko and Prives, 1996).”
BackgroundChi, S.-W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.16.4438 · Cited by 169
“The p53 protein is a transcription factor that regulates the expression of a wide variety of genes involved in cell cycle arrest and apoptosis (reviewed in Donehower and Bradley, 1993; Ko and Prives, 1996; Levine, 1997).”
BackgroundTP53 Mutations in Breast and Ovarian Cancer
Silwal-Pandit, L., Langerød, A., & Børresen-Dale, A.-L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026252 · Cited by 167
“TP53 mutations may exert a loss-of-function (LOF) effect and deprive the cells of anticancer protection, a dominant-negative effect, in which the mutant allele masks the function of the wild-type allele (Ko and Prives 1996; Willis et al. 2004), or a gain-of-function (GOF) effect and equip cells with novel tumor-promot…”
BackgroundPositioning Atypical Protein Kinase C Isoforms in the UV-Induced Apoptotic Signaling Cascade
Berra, E., Municio, M. M., Sanz, L., Frutos, S., Diaz-Meco, M. T., & Moscat, J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.8.4346 · Cited by 166
“Bax dimerizes with Bcl-2 and prevents its ability to inhibit cell death (28).”
BackgroundMethodInfluentialProteolysis by Calpains: a Possible Contribution to Degradation of p53
Pariat, M., Carillo, S., Molinari, M., Salvat, C., Debüssche, L., Bracco, L., Milner, J., & Piechaczyk, M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.5.2806 · Cited by 165
Analysis of ku80-Mutant Mice and Cells with Deficient Levels of p53
Lim, D.-S., Vogel, H., Willerford, D. M., Sands, A. T., Platt, K. A., & Hasty, P. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.3772-3780.2000 · Cited by 162
Meghvansi, M. K., Siddiqui, S., Khan, M. H., Gupta, V. K., Vairale, M. G., Gogoi, H. K., & Singh, L. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.08.034 · Cited by 161
“Some phytochemicals exert their anticancer properties by blocking cell cycle progression and triggering tumor cell apoptosis (Smets, 1994; Ko and Prives, 1996).”
BackgroundAnalysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma
Palavalli, L. H., Prickett, T. D., Wunderlich, J. R., Wei, X., Burrell, A. S., Porter-Gill, P., Davis, S., Wang, C., Cronin, J. C., Agrawal, N. S., et al. (2009) · Nature Genetics · doi:10.1038/ng.340 · Cited by 161
At the Crossroads of Inflammation and Tumorigenesis
Cordon-Cardo, C., & Prives, C. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1367 · Cited by 160
“How does MIF cause this downregulation of p53? p53 possesses the domains and properties of many other transcriptional activators (2, 3).”
BackgroundSelf-citationDickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53
Wang, J., Shou, J., & Chen, X. (2000) · Oncogene · doi:10.1038/sj.onc.1203503 · Cited by 159
Cullin 4A Associates with the UV-damaged DNA-binding Protein DDB
Shiyanov, P., Nag, A., & Raychaudhuri, P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35309 · Cited by 159
Regulation of ES cell differentiation by functional and conformational modulation of p53
Sabapathy, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6217 · Cited by 159
“…and overexpression of wild-type p53 in several cell lines often leads to reversion of the malignant phenotype or induction of apoptosis (Gottlieb and Oren, 1996; Ko and Prives, 1996). p53 acts as a tumor suppressor by preventing the propagation of DNA damage to daughter cells (Purdie et al., 1994).”
BackgroundInfluentialAdenovirus E1B 55K Represses p53 Activation In Vitro
Martin, M. E. D., & Berk, A. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.3146-3154.1998 · Cited by 159
“The cellular phosphoprotein p53 acts as a tumor suppressor, and inactivation of this function is the most prevalent alteration found in human and animal tumors (32, 35).”
BackgroundSer18 and 23 phosphorylation is required for p53‐dependent apoptosis and tumor suppression
Chao, C., Herr, D., Chun, J., & Xu, Y. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601167 · Cited by 158
p53 represses ribosomal gene transcription
Budde, A., & Grummt, I. (1999) · Oncogene · doi:10.1038/sj.onc.1202402 · Cited by 157
“It is a common target for genetic alteration in human cancers and has been implicated as a key mediator of stress-induced growth arrest or apoptosis and for suppression of cell transformation (reviewed in Levine, 1993; Oren, 1994; Ha ner and Oren, 1995; Ko and Prives, 1996; Levine, 1997).”
BackgroundThe transcription factor p53: Not a repressor, solely an activator.
Fischer, M., Steiner, L., & Engeland, K. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949083 · Cited by 153
Su, F., Overholtzer, M., Besser, D., & Levine, A. J. (2002) · Genes & Development · doi:10.1101/gad.942902 · Cited by 153
Phosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition
Cowley, D. O., & Graves, B. J. (2000) · Genes & Development · doi:10.1101/gad.14.3.366 · Cited by 152
DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation
Blattner, C., Tobiasch, E., Litfen, M., Rahmsdorf, H. J., & Herrlich, P. (1999) · Oncogene · doi:10.1038/sj.onc.1202480 · Cited by 151
Sharma, D. R., Wani, W. Y., Sunkaria, A., Kandimalla, R. J., Sharma, R. K., Verma, D., Bal, A., & Gill, K. D. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.02.055 · Cited by 144
p53 Suppresses the Activation of the Bcl-2 Promoter by the Brn-3a POU Family Transcription Factor
Budhram-Mahadeo, V., Morris, P. J., Smith, M. D., Midgley, C. A., Boxer, L. M., & Latchman, D. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.15237 · Cited by 144
Cell Type- and Promoter-specific Roles of Ser18 Phosphorylation in Regulating p53 Responses
Chao, C., Hergenhahn, M., Kaeser, M. D., Wu, Z., Saito, S., Iggo, R., Hollstein, M., Appella, E., & Xu, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306938200 · Cited by 141
Okamoto, K., Kashima, K., Pereg, Y., Ishida, M., Yamazaki, S., Nota, A., Teunisse, A., Migliorini, D., Kitabayashi, I., Marine, J.-C., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9608-9620.2005 · Cited by 129
Self-citationSolution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53
Kostic, M., Matt, T., Martinez-Yamout, M. A., Dyson, H. J., & Wright, P. E. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.08.027 · Cited by 128
Dearth, L. R., Qian, H., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl132 · Cited by 120
Cenini, G., Sultana, R., Memo, M., & Butterfield, D. A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00163.x · Cited by 117
Zaky, A., Busso, C., Izumi, T., Chattopadhyay, R., Bassiouny, A., Mitra, S., & Bhakat, K. K. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1173 · Cited by 111
“p53 is one of the most commonly mutated genes in human cancers; 50% of all human cancers lack the wild type (WT) p53 gene allele, and these tumors respond poorly to chemotherapy (32,33).”
BackgroundRecurrent inactivating RASA2 mutations in melanoma
Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J. S., Gartner, J. J., Di Pizio, A., Winograd-Katz, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3427 · Cited by 107
Liu, G., & Chen, X. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1398-1413.2006 · Cited by 104
“DNA damage stabilizes and activates p53, leading to induction of p53 target genes (25, 32, 39, 47).”
BackgroundNoncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
Jordan, J. J., Menendez, D., Inga, A., Nourredine, M., Bell, D., & Resnick, M. A. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000104 · Cited by 103
“that controls an extensive transcriptional network providing for genome integrity in response to cellular and environmental stresses or damage”
BackgroundMutation of Mouse p53 Ser23 and the Response to DNA Damage
Wu, Z., Earle, J., Saito, S., Anderson, C. W., Appella, E., & Xu, Y. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2441-2449.2002 · Cited by 103
Truncated Form of Importin α Identified in Breast Cancer Cell Inhibits Nuclear Import of p53
Kim, I.-S., Kim, D.-H., Han, S.-M., Chin, M.-U., Nam, H.-J., Cho, H.-P., Choi, S.-Y., Song, B.-J., Kim, E.-R., Bae, Y.-S., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909256199 · Cited by 99
Transcriptional modulation induced by ionizing radiation: p53 remains a central player
Rashi‐Elkeles, S., Elkon, R., Shavit, S., Lerenthal, Y., Linhart, C., Kupershtein, A., Amariglio, N., Rechavi, G., Shamir, R., & Shiloh, Y. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.06.004 · Cited by 95
Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library
Shiraishi, K., Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Sakayori, M., Ishida, T., Takeda, M., Kanamaru, R., Ohuchi, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310815200 · Cited by 96
Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells
Obad, S., Brunnström, H., Vallon-Christersson, J., Borg, Å., Drott, K., & Gullberg, U. (2004) · Oncogene · doi:10.1038/sj.onc.1207524 · Cited by 90
Cell-cycle responses to DNA damage in G2
Cuddihy, A. R., & O'Connell, M. J. (2003) · International Review of Cytology · doi:10.1016/s0074-7696(02)22013-6 · Cited by 89
Roberts, A. M., Watson, I. R., Evans, A. J., Foster, D. A., Irwin, M. S., & Ohh, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1770 · Cited by 88
“apoptosis to override the survival signals acquired by cancer cells (3, 4).”
Menendez, D., Inga, A., & Resnick, M. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2297-2308.2006 · Cited by 81
“Through coordination of over 50 genes, activated p53 is central to a variety of biological functions including cell cycling, apoptosis, differentiation, cellular senescence (28, 30, 39), angiogenesis (6, 10), and the removal of DNA damage (16, 37, 49, 60, 66).”
BackgroundHigh-Affinity Binding of Tumor-Suppressor Protein p53 and HMGB1 to Hemicatenated DNA Loops
Štros, M., Muselíková-Polanská, E., Pospíšilová, Š., & Strauss, F. (2004) · Biochemistry · doi:10.1021/bi049928k · Cited by 81
Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase
Okamoto, K., Taya, Y., & Nakagama, H. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.07.021 · Cited by 76
Watching the watcher: Regulation of p53 by mitochondria
Holley, A. K., & St Clair, D. K. (2009) · Future Oncology · doi:10.2217/14796694.5.1.117 · Cited by 75
MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation
Jackson, M. W., Lindström, M. S., & Berberich, S. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010685200 · Cited by 74
DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model
Van Nguyen, T., Puebla-Osorio, N., Pang, H., Dujka, M. E., & Zhu, C. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062453 · Cited by 72
“At the cellular level, p53 acts as a “gatekeeper” to eliminate potentially tumorigenic cells by in ducing programmed cell death, inhibiting the proliferation of damaged cells through cell cycle arrest (3), or inducing cells to withdraw from the cell cycle, referred to as cellular senescence (4, 5).”
BackgroundHudson, C. D., Morris, P. J., Latchman, D. S., & Budhram-Mahadeo, V. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408679200 · Cited by 68
Seo, Y. R., & Jung, H. J. (2004) · Experimental & Molecular Medicine · doi:10.1038/emm.2004.64 · Cited by 56
Apoptotic cell death in neurons and glial cells: implications for Alzheimer's disease
Yoshihisa, K., Takashi, T., & Shun, S. (1999) · Japanese Journal of Pharmacology · doi:10.1254/jjp.79.1 · Cited by 47
The emerging functions of the p53-miRNA network in stem cell biology
Lin, C.-P., Choi, Y. J., Hicks, G. G., & He, L. (2012) · Cell Cycle · doi:10.4161/cc.20207 · Cited by 38
“p53 functions mainly as a transcriptional factor activated in response to a variety of stimuli, such as DNA damage, hypoxia and oncogene expression.(11) Through different molecular mechanisms, these stimuli stabilize p53, leading to its accumulation”
BackgroundAbrams, S. L., Lertpiriyapong, K., Yang, L. V., Martelli, A. M., Cocco, L., Ratti, S., Falasca, M., Murata, R. M., Rosalen, P. L., Lombardi, P., et al. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.06.002 · Cited by 36
Caspase 3 Deficiency Rescues Peripheral Nervous System Defect in Retinoblastoma Nullizygous Mice
Simpson, M. T. W., MacLaurin, J. G., Xu, D., Ferguson, K. L., Vanderluit, J. L., Davoli, M. A., Roy, S., Nicholson, D. W., Robertson, G. S., Park, D. S., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07089.2001 · Cited by 35
Essential Role of Phospholipase Cγ2 in Early B-Cell Development and Myc-Mediated Lymphomagenesis
Wen, R., Chen, Y., Bai, L., Fu, G., Schuman, J., Dai, X., Zeng, H., Yang, C., Stephan, R. P., Cleveland, J. L., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00839-06 · Cited by 34
Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2
Ohtsubo, C., Shiokawa, D., Kodama, M., Gaiddon, C., Nakagama, H., Jochemsen, A. G., Taya, Y., & Okamoto, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01180.x · Cited by 32
p53 is an important regulator of CCL2 gene expression
Tang, X., Asano, M., O’Reilly, A., Farquhar, A., Yang, Y., & Amar, S. (2012) · Current Molecular Medicine · doi:10.2174/156652412802480844 · Cited by 30
“It is known that tetramerization of p53 protein contributes to its activation and high binding affinity to DNA and protein [61-63].”
BackgroundTransient exposure of a buried phosphorylation site in an autoinhibited protein
(2021) · doi:10.1016/j.bpj.2021.11.2890 · Cited by 16
Shin, M. H., Mavila, N., Wang, W.-H., Vega Alvarez, S., Hall, M. C., & Andrisani, O. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01928-08 · Cited by 14
McCubrey, J. A., Meher, A. K., Akula, S. M., Abrams, S. L., Steelman, L. S., LaHair, M. M., Franklin, R. A., Martelli, A. M., Ratti, S., Cocco, L., et al. (2022) · Aging · doi:10.18632/aging.204038 · Cited by 12
Metadata
- Authors
- Ko, L. J., & Prives, C.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 1996-05-01
- Volume
- 10
- Issue
- 9
- Pages
- 1054-1072
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2150710841
- Cited by
- 2,344
- References
- 244
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.